Increased infiltration of CD163+ TAMs in patients with pancreatic cancer is associated with a lower rate for 5-year survival and 5-year recurrence free survival, but the general presence of macrophages, designated by the pan-macrophage marker CD68, does not correlate with survival [59,62]. Here, CD163 is linked to pancreatic neoplasm.